rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.47360/1995-4484-2024-369-376rsp-3602Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESСовременные представления о диагностике и лечении остеопороза у детейCurrent concept of osteoporosis diagnosis and treatment in childrenhttps://orcid.org/0000-0003-4739-4302ТоропцоваН. В.ToroptsovaNatalia V.

Торопцова Наталья Владимировна

115522, Москва, Каширское шоссе, 34а

115522, Moscow, Kashirskoye Highway, 34A

torop@irramn.ruhttps://orcid.org/0000-0003-1842-0348НикишинаИ. П.NikishinaIrina P.

115522, Москва, Каширское шоссе, 34а

115522, Moscow, Kashirskoye Highway, 34A

https://orcid.org/0000-0002-1598-8360НасоновЕ. Л.NasonovEvgeny L.

115522, Москва, Каширское шоссе, 34а

119991, Москва, ул. Трубецкая, 8, стр. 2

115522, Moscow, Kashirskoye Highway, 34A

119991, Moscow, Trubetskaya str., 8, building 2

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian FederationФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; ФГАОУ ВО «Первый Московский государственный медицинский университет имени И.М. Сеченова» Минздрава России (Сеченовский Университет)РоссияV.A. Nasonova Research Institute of Rheumatology; I.M. Sechenov First Moscow State Medical University of the Ministry of Health Care of the Russian Federation (Sechenov University)Russian Federation202402092024624369376Copyright © Торопцова Н.В., Никишина И.П., Насонов Е.Л., 20242024Торопцова Н.В., Никишина И.П., Насонов Е.Л.Toroptsova N.V., Nikishina I.P., Nasonov E.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/3602

Остеопороз (ОП) – это заболевание, характеризующееся снижением прочности кости, приводящим к повышению риска переломов. В основе хрупкости костей у детей могут лежать генетические нарушения, хронические заболевания или применение для их лечения препаратов, отрицательно влияющих на костный метаболизм. В статье рассматривается современная классификация ОП у детей, подходы к его диагностике, роль денситометрического обследования в постановке диагноза.

Основной целью профилактики и лечения ОП является достижение более высокого пика костной массы, улучшение микроархитектоники костей, а также, как и у взрослых, снижение риска переломов, предотвращение деформаций скелета, улучшение подвижности, независимости и качества жизни. Представлены рекомендации по изменению образа жизни, включая адекватное потребление кальция и витамина D, приему антирезорбтивных препаратов, а также по ведению детей с ОП.

Osteoporosis (OP) is a disease characterized by a decrease in bone strength, leading to an increased risk of fractures. Bone fragility in children may be due to genetic disorders, chronic underlying conditions or taking medications that negatively affect bone metabolism. The article considers the modern classification of OP in children, approaches to its diagnosis, the role of dual-energy X-ray absorptiometry for diagnosis.

The main goal of OP prevention and treatment is to achieve a higher peak of bone mass, improve bone microarchitectonics, and, as in adults, reduce the risk of fractures, prevent skeletal deformities, improve mobility, independence and quality of life. Recommendations for lifestyle changes are presented, including adequate calcium intake and vitamin D, taking antiresorptive drugs, as well as prospective management of children with OP.

педиатрияостеопорозздоровье костейденситометриядиагностика остеопорозалечение остеопорозабисфосфонатыpediatricsosteoporosisbone healthdensitometrydiagnosis of osteoporosistreatment of osteoporosisbisphosphonatesReferencesBaxter-Jones AD, Faulkner RA, Forwood MR, Mirwald RL, Bailey DA. Bone mineral accrual from 8 to 30 years of age: An estimation of peak bone mass. J Bone Miner Res. 2011;26:1729-1739. doi: 10.1002/jbmr.412Baxter-Jones AD, Faulkner RA, Forwood MR, Mirwald RL, Bailey DA. Bone mineral accrual from 8 to 30 years of age: An estimation of peak bone mass. J Bone Miner Res. 2011;26:1729-1739. doi: 10.1002/jbmr.412Van Dijk FS, Pals G, Van Rijn RR, Nikkels PG, Cobben JM. Classification of osteogenesis imperfecta revisited. Eur J Med Genet. 2010;53:1-5. doi: 10.1016/j.ejmg.2009.10.007Van Dijk FS, Pals G, Van Rijn RR, Nikkels PG, Cobben JM. Classification of osteogenesis imperfecta revisited. Eur J Med Genet. 2010;53:1-5. doi: 10.1016/j.ejmg.2009.10.007Van Dijk FS. Genetics of osteoporosis in children. Endocr Dev. 2015;28:196-209. doi: 10.1159/000381046Van Dijk FS. Genetics of osteoporosis in children. Endocr Dev. 2015;28:196-209. doi: 10.1159/000381046Bregou Bourgeois A, Aubry-Rozier B, Bonafe L, Laurent-Applegate L, Pioletti DP, Zambelli PY. Osteogenesis imperfecta: From diagnosis and multidisciplinary treatment to future perspectives. Swiss Med Wkly. 2016;146:14322. doi: 10.4414/smw.2016.14322Bregou Bourgeois A, Aubry-Rozier B, Bonafe L, Laurent-Applegate L, Pioletti DP, Zambelli PY. Osteogenesis imperfecta: From diagnosis and multidisciplinary treatment to future perspectives. Swiss Med Wkly. 2016;146:14322. doi: 10.4414/smw.2016.14322Tournis S, Dede AD. Osteogenesis imperfecta – A clinical update. Metabolism. 2018;80:27-37. doi: 10.1016/j.metabol.2017.06.001Tournis S, Dede AD. Osteogenesis imperfecta – A clinical update. Metabolism. 2018;80:27-37. doi: 10.1016/j.metabol.2017.06.001Bacchetta J, Wesseling-Perry K, Gilsanz V, Gales B, Pereira RC, Salusky IB. Idiopathic juvenile osteoporosis: A cross-sectional single-centre experience with bone histomorphometry and quantitative computed tomography. Pediatr Rheumatol. 2013;11:1-8. doi: 10.1186/1546-0096-11-6Bacchetta J, Wesseling-Perry K, Gilsanz V, Gales B, Pereira RC, Salusky IB. Idiopathic juvenile osteoporosis: A cross-sectional single-centre experience with bone histomorphometry and quantitative computed tomography. Pediatr Rheumatol. 2013;11:1-8. doi: 10.1186/1546-0096-11-6Franceschi R, Vincenzi M, Camilot M, Antoniazzi F, Freemont AJ, Adams JE, et al. Idiopathic juvenile osteoporosis: Clinical experience from a single centre and screening of LRP5 and LRP6 genes. Calcif Tissue Int. 2015;96:575-579. doi: 10.1007/s00223-015-9983-7Franceschi R, Vincenzi M, Camilot M, Antoniazzi F, Freemont AJ, Adams JE, et al. Idiopathic juvenile osteoporosis: Clinical experience from a single centre and screening of LRP5 and LRP6 genes. Calcif Tissue Int. 2015;96:575-579. doi: 10.1007/s00223-015-9983-7Galindo-Zavala R, Bou-Torrent R, Magallares-López B, MirPerelló C, Palmou-Fontana N, Sevilla-Pérez B, et al. Expert panel consensus recommendations for diagnosis and treatment of secondary osteoporosis in children. Pediatr Rheumatol Online J. 2020;18(1):20. doi: 10.1186/s12969-020-0411-9Galindo-Zavala R, Bou-Torrent R, Magallares-López B, MirPerelló C, Palmou-Fontana N, Sevilla-Pérez B, et al. Expert panel consensus recommendations for diagnosis and treatment of secondary osteoporosis in children. Pediatr Rheumatol Online J. 2020;18(1):20. doi: 10.1186/s12969-020-0411-9Cooper C, Dennison EM, Leufkens HG, Bishop N, van Staa TP. Epidemiology of childhood fractures in Britain: A study using the general practice research database. J Bone Miner Res. 2004;19(12):1976-1981. doi: 10.1359/JBMR.040902Cooper C, Dennison EM, Leufkens HG, Bishop N, van Staa TP. Epidemiology of childhood fractures in Britain: A study using the general practice research database. J Bone Miner Res. 2004;19(12):1976-1981. doi: 10.1359/JBMR.040902Clark EM. The epidemiology of fractures in otherwise healthy children. Curr Osteoporos Rep. 2014;12(3):272-278. doi: 10.1007/s11914-014-0227-yClark EM. The epidemiology of fractures in otherwise healthy children. Curr Osteoporos Rep. 2014;12(3):272-278. doi: 10.1007/s11914-014-0227-yMäyränpää MK, Mäkitie O, Kallio PE. Decreasing incidence and changing pattern of childhood fractures: A population-based study. J Bone Miner Res. 2010;25(12):2752-2759. doi: 10.1002/jbmr.155Mäyränpää MK, Mäkitie O, Kallio PE. Decreasing incidence and changing pattern of childhood fractures: A population-based study. J Bone Miner Res. 2010;25(12):2752-2759. doi: 10.1002/jbmr.155Fiscaletti M, Coorey CP, Biggin A, Briody J, Little DG, Schindeler A, et al. Diagnosis of recurrent fracture in a pediatric cohort. Calcif Tissue Int. 2018;103(5):529-539. doi: 10.1007/s00223-018-0449-6Fiscaletti M, Coorey CP, Biggin A, Briody J, Little DG, Schindeler A, et al. Diagnosis of recurrent fracture in a pediatric cohort. Calcif Tissue Int. 2018;103(5):529-539. doi: 10.1007/s00223-018-0449-6Rauch F, Bailey DA, Baxter-Jones A, Mirwald R, Faulkner R. The ‘muscle-bone unit’ during the pubertal growth spurt. Bone. 2004;34(5):771-775. doi: 10.1016/j.bone.2004.01.022Rauch F, Bailey DA, Baxter-Jones A, Mirwald R, Faulkner R. The ‘muscle-bone unit’ during the pubertal growth spurt. Bone. 2004;34(5):771-775. doi: 10.1016/j.bone.2004.01.022Bishop N, Arundel P, Clark E, Dimitri P, Farr J, Jones G, et al. Fracture prediction and the definition of osteoporosis in children and adolescents: The ISCD 2013 Pediatric Official Positions. J Clin Densitom. 2014;17(2):275-280. doi: 10.1016/j.jocd.2014.01.004Bishop N, Arundel P, Clark E, Dimitri P, Farr J, Jones G, et al. Fracture prediction and the definition of osteoporosis in children and adolescents: The ISCD 2013 Pediatric Official Positions. J Clin Densitom. 2014;17(2):275-280. doi: 10.1016/j.jocd.2014.01.004Baim S, Leonard MB, Bianchi ML, Hans DB, Kalkwarf HJ, Langman CB, et al. Official positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Pediatric Position Development Conference. J Clin Densitom. 2008;11(1):6-21. doi: 10.1016/j.jocd.2007.12.002Baim S, Leonard MB, Bianchi ML, Hans DB, Kalkwarf HJ, Langman CB, et al. Official positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Pediatric Position Development Conference. J Clin Densitom. 2008;11(1):6-21. doi: 10.1016/j.jocd.2007.12.002Ward LM, Weber DR, Munns CF, Högler W, Zemel BS. A contemporary view of the definition and diagnosis of osteoporosis in children and adolescents. J Clin Endocrinol Metab. 2020;105(5):2088-2097. doi: 10.1210/clinem/dgz294Ward LM, Weber DR, Munns CF, Högler W, Zemel BS. A contemporary view of the definition and diagnosis of osteoporosis in children and adolescents. J Clin Endocrinol Metab. 2020;105(5):2088-2097. doi: 10.1210/clinem/dgz294Ward LM, Ma J, Lang B, Ho J, Alos N, Matzinger MA, et al.; Steroid-Associated Osteoporosis in the Pediatric Population (STOPP) Consortium. Bone morbidity and recovery in children with acute lymphoblastic leukemia: Results of a six-year prospective cohort study. J Bone Miner Res. 2018;33(8):1435-1443. doi: 10.1002/jbmr.3447Ward LM, Ma J, Lang B, Ho J, Alos N, Matzinger MA, et al.; Steroid-Associated Osteoporosis in the Pediatric Population (STOPP) Consortium. Bone morbidity and recovery in children with acute lymphoblastic leukemia: Results of a six-year prospective cohort study. J Bone Miner Res. 2018;33(8):1435-1443. doi: 10.1002/jbmr.3447Kocks J, Ward K, Mughal Z, Moncayo R, Adams J, Högler W. Z-score comparability of bone mineral density reference databases for children. J Clin Endocrinol Metab. 2010;95(10):4652-4659. doi: 10.1210/jc.2010-0677Kocks J, Ward K, Mughal Z, Moncayo R, Adams J, Högler W. Z-score comparability of bone mineral density reference databases for children. J Clin Endocrinol Metab. 2010;95(10):4652-4659. doi: 10.1210/jc.2010-0677Ma J, Siminoski K, Also N, Halton J, Ho J, Lentle B, et al.; Canadian STOPP Consortium. The choice of normative pediatric reference database changes spine bone mineral density Z-scores but not the relationship between bone mineral density and prevalent vertebral fractures. J Clin Endocrinol Metab. 2015;100(3):1018-1027. doi: 10.1210/jc.2014-3096Ma J, Siminoski K, Also N, Halton J, Ho J, Lentle B, et al.; Canadian STOPP Consortium. The choice of normative pediatric reference database changes spine bone mineral density Z-scores but not the relationship between bone mineral density and prevalent vertebral fractures. J Clin Endocrinol Metab. 2015;100(3):1018-1027. doi: 10.1210/jc.2014-3096Bardai G, Moffatt P, Glorieux FH, Rauch F. DNA sequence analysis in 598 individuals with a clinical diagnosis of osteogenesis imperfecta: Diagnostic yield and mutation spectrum. Osteoporos Int. 2016;27(12):3607-3613. doi: 10.1007/s00198-016-3709-1Bardai G, Moffatt P, Glorieux FH, Rauch F. DNA sequence analysis in 598 individuals with a clinical diagnosis of osteogenesis imperfecta: Diagnostic yield and mutation spectrum. Osteoporos Int. 2016;27(12):3607-3613. doi: 10.1007/s00198-016-3709-1Ma J, McMillan HJ, Karagüzel G, Goodin C, Wasson J, Matzinger MA, et al. The time to and determinants of first fractures in boys with Duchenne muscular dystrophy. Osteoporos Int. 2017;28(2):597-608. doi: 10.1007/s00198-016-3774-5Ma J, McMillan HJ, Karagüzel G, Goodin C, Wasson J, Matzinger MA, et al. The time to and determinants of first fractures in boys with Duchenne muscular dystrophy. Osteoporos Int. 2017;28(2):597-608. doi: 10.1007/s00198-016-3774-5Ben Amor IM, Roughley P, Glorieux FH, Rauch F. Skeletal clinical characteristics of osteogenesis imperfecta caused by haploinsufficiency mutations in COL1A1. J Bone Miner Res. 2013;28(9):2001-2007. doi: 10.1002/jbmr.1942Ben Amor IM, Roughley P, Glorieux FH, Rauch F. Skeletal clinical characteristics of osteogenesis imperfecta caused by haploinsufficiency mutations in COL1A1. J Bone Miner Res. 2013;28(9):2001-2007. doi: 10.1002/jbmr.1942Singh A, Schaeffer EK, Reilly CW. Vertebral fractures in Duchenne muscular dystrophy patients managed with deflazacort. J Pediatr Orthop. 2018;38(6):320-324. doi: 10.1097/BPO.0000000000000817singh a, schaeffer ek, reilly cw. vertebral fractures in duchenne muscular dystrophy patients managed with deflazacort. j pediatr orthop. 2018;38(6):320-324. doi: 10.1097/bpo.0000000000000817Szulc P, Seeman E, Delmas PD. Biochemical measurements of bone turnover in children and adolescents. Osteoporos Int. 2000;11(4):281-294. doi: 10.1007/s001980070116Szulc P, Seeman E, Delmas PD. Biochemical measurements of bone turnover in children and adolescents. Osteoporos Int. 2000;11(4):281-294. doi: 10.1007/s001980070116Crabtree NJ, Arabi A, Bachrach LK, Fewtrell M, Fuleihan GEH, Kecskemethy HH, et al. International Society for Clinical D Dualenergy X-ray absorptiometry interpretation and reporting in children and adolescents: The revised 2013 ISCD pediatric official positions. J Clin Densitom. 2014;17:225-242. doi: 10.1016/j.jocd.2014.01.003Crabtree NJ, Arabi A, Bachrach LK, Fewtrell M, Fuleihan GEH, Kecskemethy HH, et al. International Society for Clinical D Dualenergy X-ray absorptiometry interpretation and reporting in children and adolescents: The revised 2013 ISCD pediatric official positions. J Clin Densitom. 2014;17:225-242. doi: 10.1016/j.jocd.2014.01.003Kalkwarf HJ, Abrams SA, DiMeglio LA, Koo WW, Specker BL, Weiler H. Bone densitometry in infants and young children: The 2013 ISCD pediatric official positions. J Clin Densitom. 2014;17:243-257. doi: 10.1016/j.jocd.2014.01.002Kalkwarf HJ, Abrams SA, DiMeglio LA, Koo WW, Specker BL, Weiler H. Bone densitometry in infants and young children: The 2013 ISCD pediatric official positions. J Clin Densitom. 2014;17:243-257. doi: 10.1016/j.jocd.2014.01.002Weber DR, Boyce A, Gordon C, Hogler W, Kecskemethy HH, et al. The utility of DXA assessment at the forearm, proximal femur, and lateral distal femur, and vertebral fracture assessment in the pediatric population: 2019 ISCD official position. J Clin Densitom. 2019;22:567-589. doi: 10.1016/j.jocd.2019.07.002Weber DR, Boyce A, Gordon C, Hogler W, Kecskemethy HH, et al. The utility of DXA assessment at the forearm, proximal femur, and lateral distal femur, and vertebral fracture assessment in the pediatric population: 2019 ISCD official position. J Clin Densitom. 2019;22:567-589. doi: 10.1016/j.jocd.2019.07.002Zemel BS, Leonard MB, Kelly A, Lappe JM, Gilsanz V, Oberfield S, et al. Height adjustment in assessing dual energy X-ray absorptiometry measurements of bone mass and density in children. J Clin Endocrinol Metab. 2010;95(3):1265-1273. doi: 10.1210/jc.2009-2057Zemel BS, Leonard MB, Kelly A, Lappe JM, Gilsanz V, Oberfield S, et al. Height adjustment in assessing dual energy X-ray absorptiometry measurements of bone mass and density in children. J Clin Endocrinol Metab. 2010;95(3):1265-1273. doi: 10.1210/jc.2009-2057Alqahtani FF, Offiah AC. Diagnosis of osteoporotic vertebral fractures in children. Pediatr Radiol. 2019;49:283-296. doi: 10.1007/s00247-018-4279-5Alqahtani FF, Offiah AC. Diagnosis of osteoporotic vertebral fractures in children. Pediatr Radiol. 2019;49:283-296. doi: 10.1007/s00247-018-4279-5Genant HK, Wu CY, Van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res. 1993;8:1137-1148. doi: 10.1002/jbmr.5650080915Genant HK, Wu CY, Van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res. 1993;8:1137-1148. doi: 10.1002/jbmr.5650080915Crabtree NJ, Chapman S, Hogler W, Hodgson K, Chapman D, Bebbington N, et al. Vertebral fractures assessment in children: Evaluation of DXA imaging versus conventional spine radiography. Bone. 2017;97:168-174. doi: 10.1016/j.bone.2017.01.006Crabtree NJ, Chapman S, Hogler W, Hodgson K, Chapman D, Bebbington N, et al. Vertebral fractures assessment in children: Evaluation of DXA imaging versus conventional spine radiography. Bone. 2017;97:168-174. doi: 10.1016/j.bone.2017.01.006Национальная программа по оптимизации обеспеченности витаминами и минеральными веществами детей России. М.:Педиатръ;2017.National program for optimizing the provision of vitamins and minerals to children in Russia. Moscow:Pediatr;2017. (In Russ.)].Национальная программа «Недостаточность витамина D у детей и подростков Российской Федерации: современные подходы к коррекции». М.:Педиатръ;2018. [National program “Vitamin D deficiency in children and adolescents of the Russian ederation: Modern approaches to correction”. Moscow:Pediatr;2018. (In Russ.)].Национальная программа «Недостаточность витамина D у детей и подростков Российской Федерации: современные подходы к коррекции». М.:Педиатръ;2018. [National program “Vitamin D deficiency in children and adolescents of the Russian ederation: Modern approaches to correction”. Moscow:Pediatr;2018. (In Russ.)].Hoyer-Kuhn H, Semler O, Stark C, Struebing N, Goebel O, Schoenau E. A specialized rehabilitation approach improves mobility in children with osteogenesis imperfecta. J Musculoskelet Neuronal Interact. 2014;14:445-453.Hoyer-Kuhn H, Semler O, Stark C, Struebing N, Goebel O, Schoenau E. A specialized rehabilitation approach improves mobility in children with osteogenesis imperfecta. J Musculoskelet Neuronal Interact. 2014;14:445-453.Papapoulos SE, Cremers SC. Prolonged bisphosphonate release after treatment in children. N Engl J Med. 2007;356:1075-1076. doi: 10.1056/NEJMc062792Papapoulos SE, Cremers SC. Prolonged bisphosphonate release after treatment in children. N Engl J Med. 2007;356:1075-1076. doi: 10.1056/NEJMc062792Högler W, Yap F, Little D, Ambler G, McQuade M, Cowell CT. Short-term safety assessment in the use of intravenous zoledronic acid in children. J Pediatr. 2004;145:701-704. doi: 1016/j.jpeds.2004.06.066Högler W, Yap F, Little D, Ambler G, McQuade M, Cowell CT. Short-term safety assessment in the use of intravenous zoledronic acid in children. J Pediatr. 2004;145:701-704. doi: 1016/j.jpeds.2004.06.066Munns CF, Rauch F, Mier RJ, Glorieux FH. Respiratory distress with pamidronate treatment in infants with severe osteogenesis imperfecta. Bone. 2004;35:231-234. doi: 10.1016/j.bone.2004.03.008Munns CF, Rauch F, Mier RJ, Glorieux FH. Respiratory distress with pamidronate treatment in infants with severe osteogenesis imperfecta. Bone. 2004;35:231-234. doi: 10.1016/j.bone.2004.03.008Ward L, Tricco AC, Phuong P, Cranney A, Barrowman N, Gaboury I, et al. Bisphosphonate therapy for children and adolescents with secondary osteoporosis. Cochrane Database Syst Rev. 2007;CD005324. doi: 10.1002/14651858.CD005324.pub2Ward L, Tricco AC, Phuong P, Cranney A, Barrowman N, Gaboury I, et al. Bisphosphonate therapy for children and adolescents with secondary osteoporosis. Cochrane Database Syst Rev. 2007;CD005324. doi: 10.1002/14651858.CD005324.pub2Munns CF, Rauch F, Zeitlin L, Fassier F, Glorieux FH. Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate. J Bone Min Res. 2004;19:1779-1786. doi: 10.1359/jbmr.040814Munns CF, Rauch F, Zeitlin L, Fassier F, Glorieux FH. Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate. J Bone Min Res. 2004;19:1779-1786. doi: 10.1359/jbmr.040814Acott PD, Wong JA, Lang BA, Crocker JF. Pamidronate treatment of pediatric fracture patients on chronic steroid therapy. Pediatr Nephrol. 2005;20(3):368-373. doi: 10.1007/s00467-004-1790-8Acott PD, Wong JA, Lang BA, Crocker JF. Pamidronate treatment of pediatric fracture patients on chronic steroid therapy. Pediatr Nephrol. 2005;20(3):368-373. doi: 10.1007/s00467-004-1790-8Bianchi ML, Cimaz R, Bardare M, Zulian F, Lepore L, Boncompagli A, et al. Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children: A prospective multicenter study. Arthritis Rheum. 2000;43:19601966. doi: 10.1002/1529-0131(200009)43:9<1960::AIDANR6>3.0.CO;2-JBianchi ML, Cimaz R, Bardare M, Zulian F, Lepore L, Boncompagli A, et al. Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children: A prospective multicenter study. Arthritis Rheum. 2000;43:19601966. doi: 10.1002/1529-0131(200009)43:9<1960::AIDANR6>3.0.CO;2-JRudge S, Hailwood S, Horne A, Lucas J, Wu F, Cundy T. Effects of once-weekly oral alendronate on bone in children on glucocorticoid treatment. Rheumatology. 2005;44:813-818. doi: 10.1093/rheumatology/keh538Rudge S, Hailwood S, Horne A, Lucas J, Wu F, Cundy T. Effects of once-weekly oral alendronate on bone in children on glucocorticoid treatment. Rheumatology. 2005;44:813-818. doi: 10.1093/rheumatology/keh538Ward LM, Choudhury A, Alos N, Cabral DA, Rodd C, Sbrocci AM, et al. Zoledronic acid vs placebo in pediatric glucocorticoid-induced osteoporosis: A randomized, double-blind, phase 3 trial. J Clin Endocrinol Metab. 2021:106:5222-e5235. doi: 10.1210/clinem/dgab458Ward LM, Choudhury A, Alos N, Cabral DA, Rodd C, Sbrocci AM, et al. Zoledronic acid vs placebo in pediatric glucocorticoid-induced osteoporosis: A randomized, double-blind, phase 3 trial. J Clin Endocrinol Metab. 2021:106:5222-e5235. doi: 10.1210/clinem/dgab458Simm PJ, Biggin A, Zacharin MR, Rodda CP, Tham E, Siafarikas A, et al.; Group ABMW. Consensus guidelines on the use of bisphosphonate therapy in children and adolescents. J Paediatr Child Health. 2018;54:223-233. doi: 10.1111/jpc.13768Simm PJ, Biggin A, Zacharin MR, Rodda CP, Tham E, Siafarikas A, et al.; Group ABMW. Consensus guidelines on the use of bisphosphonate therapy in children and adolescents. J Paediatr Child Health. 2018;54:223-233. doi: 10.1111/jpc.13768Boyce AM. Denosumab: An emerging therapy in pediatric bone disorders. Curr Osteoporos Rep. 2017:15:283-292. doi: 10.1007/s11914-017-0380-1Boyce AM. Denosumab: An emerging therapy in pediatric bone disorders. Curr Osteoporos Rep. 2017:15:283-292. doi: 10.1007/s11914-017-0380-1Open-label extension denosumab study in children and young adults with osteogenesis imperfecta. ClinicalTrials.gov Identifier: NCT03638128. 2022.Open-label extension denosumab study in children and young adults with osteogenesis imperfecta. ClinicalTrials.gov Identifier: NCT03638128. 2022.Wang HD, Boyce AM, Tsai JY, Gafni RI, Farley FA, KasaVubu JZ, et al. Effects of denosumab treatment and discontinuation on human growth plates. J Clin Endocrinol Metab. 2014:99:891-897. doi: 10.1210/jc.2013-3081Wang HD, Boyce AM, Tsai JY, Gafni RI, Farley FA, KasaVubu JZ, et al. Effects of denosumab treatment and discontinuation on human growth plates. J Clin Endocrinol Metab. 2014:99:891-897. doi: 10.1210/jc.2013-3081Uday S, Gaston CL, Rogers L, Parry M, Joffe J, Pearson J, et al. Osteonecrosis of the jaw and rebound hypercalcemia in young people treated with denosumab for giant cell tumor of bone. J Clin Endocrinol Metab. 2018:103:596-603. doi: 10.1210/jc.2017-02025Uday S, Gaston CL, Rogers L, Parry M, Joffe J, Pearson J, et al. Osteonecrosis of the jaw and rebound hypercalcemia in young people treated with denosumab for giant cell tumor of bone. J Clin Endocrinol Metab. 2018:103:596-603. doi: 10.1210/jc.2017-02025Mariz BALA, Migliorati CA, Alves FA, Penteado FM, Carvalho NP Filho, Santos-Silva AR, et al. Successful denosumab treatment for central giant cell granuloma in a 9-year-old child. Spec Care Dentist. 2021;41:519-525. doi: 10.1111/scd.12588Mariz BALA, Migliorati CA, Alves FA, Penteado FM, Carvalho NP Filho, Santos-Silva AR, et al. Successful denosumab treatment for central giant cell granuloma in a 9-year-old child. Spec Care Dentist. 2021;41:519-525. doi: 10.1111/scd.12588Horiuchi K, Kobayashi E, Mizuno T, Susa M, Chiba K. Hypercalcemia following discontinuation of denosumab therapy: A systematic review. Bone Rep. 2021;15:101148. doi: 10.1016/j.bonr.2021.101148Horiuchi K, Kobayashi E, Mizuno T, Susa M, Chiba K. Hypercalcemia following discontinuation of denosumab therapy: A systematic review. Bone Rep. 2021;15:101148. doi: 10.1016/j.bonr.2021.101148Ciancia S, Högler W, Sakkers RJB, Appelman-Dijkstra NM, Boot AM, Sas TCJ, et al. Osteoporosis in children and adolescents: How to treat and monitor? Eur J Pediatr. 2023;182(2):501-511. doi: 10.1007/s00431-022-04743-xCiancia S, Högler W, Sakkers RJB, Appelman-Dijkstra NM, Boot AM, Sas TCJ, et al. Osteoporosis in children and adolescents: How to treat and monitor? Eur J Pediatr. 2023;182(2):501-511. doi: 10.1007/s00431-022-04743-xStudy to evaluate efficacy and safety of romosozumab compared with bisphosphonates in children and adolescents with osteogenesis imperfecta. ClinicalTrials.gov Identifier: NCT05972551. 2023.Study to evaluate efficacy and safety of romosozumab compared with bisphosphonates in children and adolescents with osteogenesis imperfecta. ClinicalTrials.gov Identifier: NCT05972551. 2023.Humphrey MB, Russell L, Danila MI, Fink HA, Guyatt G, Cannon M, et al. 2022 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken). 2023;75(12):2405-2419. doi: 10.1002/acr.25240Humphrey MB, Russell L, Danila MI, Fink HA, Guyatt G, Cannon M, et al. 2022 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken). 2023;75(12):2405-2419. doi: 10.1002/acr.25240Ward LM. Glucocorticoid-induced osteoporosis: Why kids are different. Front Endocrinol (Lausanne). 2020;11:576. doi: 10.3389/fendo.2020.00576Ward LM. Glucocorticoid-induced osteoporosis: Why kids are different. Front Endocrinol (Lausanne). 2020;11:576. doi: 10.3389/fendo.2020.00576Godbout A, Tejedor I, Malivoir S, Polak M, Touraine P. Transition from pediatric to adult healthcare: Assessment of specific needs of patients with chronic endocrine conditions. Horm Res Paediatr. 2012;78:247-255. doi: 10.1159/000343818Godbout A, Tejedor I, Malivoir S, Polak M, Touraine P. Transition from pediatric to adult healthcare: Assessment of specific needs of patients with chronic endocrine conditions. Horm Res Paediatr. 2012;78:247-255. doi: 10.1159/000343818

The authors declare that there are no conflicts of interest present.